Skip to Content
Merck
  • Blockade of IL-22 signaling reverses erythroid dysfunction in stress-induced anemias.

Blockade of IL-22 signaling reverses erythroid dysfunction in stress-induced anemias.

Nature immunology (2021-03-24)
Mahesh Raundhal, Shrestha Ghosh, Samuel A Myers, Michael S Cuoco, Meromit Singer, Steven A Carr, Sushrut S Waikar, Joseph V Bonventre, Jerome Ritz, Richard M Stone, David P Steensma, Aviv Regev, Laurie H Glimcher
ABSTRACT

Patients with myelodysplastic syndromes (MDSs) display severe anemia but the mechanisms underlying this phenotype are incompletely understood. Right open-reading-frame kinase 2 (RIOK2) encodes a protein kinase located at 5q15, a region frequently lost in patients with MDS del(5q). Here we show that hematopoietic cell-specific haploinsufficient deletion of Riok2 (Riok2f/+Vav1cre) led to reduced erythroid precursor frequency leading to anemia. Proteomic analysis of Riok2f/+Vav1cre erythroid precursors suggested immune system activation, and transcriptomic analysis revealed an increase in p53-dependent interleukin (IL)-22 in Riok2f/+Vav1cre CD4+ T cells (TH22). Further, we discovered that the IL-22 receptor, IL-22RA1, was unexpectedly present on erythroid precursors. Blockade of IL-22 signaling alleviated anemia not only in Riok2f/+Vav1cre mice but also in wild-type mice. Serum concentrations of IL-22 were increased in the subset of patients with del(5q) MDS as well as patients with anemia secondary to chronic kidney disease. This work reveals a possible therapeutic opportunity for reversing many stress-induced anemias by targeting IL-22 signaling.

MATERIALS
Product Number
Brand
Product Description

Millipore
SMC® Human IL-22 High Sensitivity Kit, 1 kit sufficient for 96 wells, input: serum, plasma